Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A standardised approach to the pathological dissection and reporting of pelvic exenteration specimens: Recommendations from the UK Pelvic Exenteration Network (UKPEN).

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2026
Same author

Defining Standard Data Reporting in Pelvic Exenterations for Non-Rectal Cancers: A Systematic Review of Current Data Reporting.

Cancers·2025
Same author

Opening the operating theatre to oncology: treatment of locally recurrent rectal cancer with peritoneal metastasis by simultaneous hyperthermic intraperitoneal chemotherapy and intraoperative electron beam radiotherapy.

Annals of the Royal College of Surgeons of England·2025
Same author

Multivisceral Resection of Advanced Pelvic Tumors: From Planning to Implementation.

Clinics in colon and rectal surgery·2020
Same author

The impact of COVID-19 on advanced colorectal cancer.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2020
Same author

Session 2: Mutational discordance: the big challenge in personalized treatments - any solutions?

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2018

Related Experiment Video

Updated: Jan 22, 2026

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

21.5K

Immuno-oncology for surgeons.

S L Lee1,2,3, A Al-Shamkhani2, A Mirnezami1,3

  • 1Southampton Cancer Research UK Centre, University of Southampton, Southampton, UK.

The British Journal of Surgery
|July 19, 2019
PubMed
Summary
This summary is machine-generated.

Immuno-oncology therapies are revolutionizing cancer care, offering new ways to mobilize the immune system against cancer. This review updates surgeons on these agents, their toxicities, and their integration with cancer surgery.

More Related Videos

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.3K
Principles of Rodent Surgery for the New Surgeon
10:29

Principles of Rodent Surgery for the New Surgeon

Published on: January 6, 2011

117.0K

Related Experiment Videos

Last Updated: Jan 22, 2026

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

21.5K
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.3K
Principles of Rodent Surgery for the New Surgeon
10:29

Principles of Rodent Surgery for the New Surgeon

Published on: January 6, 2011

117.0K

Area of Science:

  • Oncology
  • Immunology
  • Genomics
  • Molecular Biology

Background:

  • Traditional cancer treatments focus on targeting neoplastic cells directly.
  • Advances in genomics and molecular techniques enable personalized cancer therapies.
  • Immunology breakthroughs provide a mechanistic understanding of immune system mobilization against cancer.

Purpose of the Study:

  • To provide an update on immuno-oncology agents for surgical oncologists.
  • To discuss the mechanisms of action of current immuno-oncology therapies.
  • To summarize emerging toxicities and data on combining surgery with immuno-oncology.

Main Methods:

  • Review of current immuno-oncology agents and their mechanisms.
  • Discussion of surgically relevant toxicities associated with immuno-oncology.
  • Summary of clinical data on sequencing and combining cancer surgery with immuno-oncology treatments.

Main Results:

  • Immuno-oncology agents are rapidly transforming cancer care.
  • Clinical trials of immune-modifying agents have increased exponentially.
  • Surgical oncologists will increasingly manage patients treated with neoadjuvant or adjuvant immuno-oncology.

Conclusions:

  • Immuno-oncology represents a significant advancement in cancer treatment.
  • Understanding immuno-oncology mechanisms and toxicities is crucial for surgeons.
  • Integration of immuno-oncology with surgical interventions is a key area for future cancer care.